Trince

Trince

A new paradigm for enhanced cell transfections.

  • Edit
Get premium to view all results
DateInvestorsAmountRound
-investor

€0.0

round
investor investor

€0.0

round

€2.0m

Seed
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
EUR20222023
Revenues00000000
EBITDA00000000
Profit00000000
EV00000000
EV / revenue00.0x00.0x
EV / EBITDA00.0x00.0x
R&D budget00000000

Source: Company filings or news article

More about Trince
Edit

Trince, a Belgian company based in Ghent, devlops the LumiPore platform, a revolutionary intracellular delivery technology facilitating the transport of functional compounds into cells. With a focus on genetic engineering, Trince targets immune cells for cancer therapy, stem cells like iPSCs, and live cell imaging. Their technology enables precise genetic modifications while preserving cell function and therapeutic potential. Using pulsed laser light and photothermal nanoparticles, Trince achieves localized forces to create temporary pores in cell membranes, termed "photoporation." This approach allows efficient, flexible, and safe delivery of molecules into various cell types. Particularly suitable for R&D, the technology involves adding nano sensitizers to cell culture and laser irradiation. For clinical use, Trince embeds nano sensitizers into polymer nanofibers or recommends biodegradable options. Recent studies demonstrate its efficacy in CAR T cell therapy. Trince continues to advance genetic engineering research for therapeutic applications.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads